David A. Egan

8.2k total citations · 3 hit papers
81 papers, 4.9k citations indexed

About

David A. Egan is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, David A. Egan has authored 81 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Molecular Biology, 16 papers in Oncology and 10 papers in Immunology. Recurrent topics in David A. Egan's work include Renin-Angiotensin System Studies (7 papers), Cell Image Analysis Techniques (7 papers) and Receptor Mechanisms and Signaling (6 papers). David A. Egan is often cited by papers focused on Renin-Angiotensin System Studies (7 papers), Cell Image Analysis Techniques (7 papers) and Receptor Mechanisms and Signaling (6 papers). David A. Egan collaborates with scholars based in Netherlands, United States and United Kingdom. David A. Egan's co-authors include Remco Nagel, Carlos le Sage, Reuven Agami, Mariëtte Schrier, Ronald M. Evans, Thomas F. Holzman, Silvia Anna Ciafrè, Annunziato Mangiola, Elly Mesman and Neri Mercatelli and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

David A. Egan

81 papers receiving 4.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis

2008 800 citations David A. Egan et al. profile →
Regulation of the p27Kip1 tumor suppressor by miR‐221 and miR‐222 promotes cancer cell proliferation

2007 651 citations David A. Egan et al. profile →
Intra-tumour diversification in colorectal cancer at the single-cell level

2018 376 citations David A. Egan et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David A. Egan Netherlands	31	3.4k	1.6k	1.0k	517	409	81	4.9k
Marie Arsenian‐Henriksson Sweden	41	4.3k 1.3×	1.6k 1.0×	1.5k 1.5×	783 1.5×	410 1.0×	101	6.3k
Emily I. Chen United States	34	2.6k 0.8×	1.1k 0.7×	1.4k 1.3×	385 0.7×	441 1.1×	55	4.4k
Anna Asplund Sweden	32	3.7k 1.1×	983 0.6×	723 0.7×	450 0.9×	346 0.8×	71	5.3k
Venu Raman United States	39	4.1k 1.2×	1.9k 1.2×	1.9k 1.8×	504 1.0×	346 0.8×	101	6.5k
Maode Lai China	37	3.1k 0.9×	1.8k 1.1×	831 0.8×	396 0.8×	214 0.5×	109	4.5k
Matthias Nees Finland	35	2.3k 0.7×	882 0.6×	1.1k 1.1×	378 0.7×	320 0.8×	78	4.1k
Michael K. Wendt United States	41	2.4k 0.7×	940 0.6×	1.5k 1.4×	602 1.2×	349 0.9×	105	4.7k
Enrico Giraudo Italy	34	2.4k 0.7×	1.0k 0.6×	1.5k 1.4×	849 1.6×	426 1.0×	60	4.5k
Reinhold Schäfer Germany	41	3.8k 1.1×	1.1k 0.7×	1.3k 1.3×	961 1.9×	750 1.8×	132	5.9k
Tim R. Fenton United Kingdom	27	2.7k 0.8×	1.3k 0.8×	1.2k 1.1×	508 1.0×	292 0.7×	51	4.8k

Countries citing papers authored by David A. Egan

Since Specialization

Citations

This map shows the geographic impact of David A. Egan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Egan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Egan more than expected).

Fields of papers citing papers by David A. Egan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Egan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Egan. The network helps show where David A. Egan may publish in the future.

Co-authorship network of co-authors of David A. Egan

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Egan. A scholar is included among the top collaborators of David A. Egan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Egan. David A. Egan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bate-Eya, Laurel T., Lindy K. Alles, Linda Schild, et al.. (2021). High-Throughput Screening Identifies Idasanutlin as a Resensitizing Drug for Venetoclax-Resistant Neuroblastoma Cells. Molecular Cancer Therapeutics. 20(6). 1161–1172. 9 indexed citations

Velden, Lieke M. van der, René H. Medema, Arno Siebes, et al.. (2020). Combining Supervised and Unsupervised Machine Learning Methods for Phenotypic Functional Genomics Screening. SLAS DISCOVERY. 25(6). 655–664. 15 indexed citations

Klumperman, Judith, et al.. (2017). Improving Comprehension Efficiency of High Content Screening Data Through Interactive Visualizations. Assay and Drug Development Technologies. 15(6). 247–256. 3 indexed citations

Kruitwagen, Hedwig S., Bart Westendorp, Cornelia S. Viebahn, et al.. (2017). DYRK1A Is a Regulator of S-Phase Entry in Hepatic Progenitor Cells. Stem Cells and Development. 27(2). 133–146. 5 indexed citations

Pagliero, Romina J., Lieke M. van der Velden, Daphne Lelieveld, et al.. (2016). HC StratoMineR: A Web-Based Tool for the Rapid Analysis of High-Content Datasets. Assay and Drug Development Technologies. 14(8). 439–452. 12 indexed citations

Pagliero, Romina J., Diego S. D’Astolfo, Daphne Lelieveld, et al.. (2016). Discovery of Small Molecules That Induce Lysosomal Cell Death in Cancer Cell Lines Using an Image-Based Screening Platform. Assay and Drug Development Technologies. 14(8). 489–510. 17 indexed citations

Heesbeen, Roy G. H. P. van, Jonne A. Raaijmakers, Marvin E. Tanenbaum, et al.. (2016). Aurora A, MCAK, and Kif18b promote Eg5-independent spindle formation. Chromosoma. 126(4). 473–486. 30 indexed citations

Kuiken, Hendrik J., David A. Egan, Heike Laman, et al.. (2012). Identification of F‐box only protein 7 as a negative regulator of NF‐kappaB signalling. Journal of Cellular and Molecular Medicine. 16(9). 2140–2149. 33 indexed citations

Stuart, A. A. Verrijn, Henk S. Schipper, David A. Egan, et al.. (2011). Altered Plasma Adipokine Levels andin VitroAdipocyte Differentiation in Pediatric Type 1 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 97(2). 463–472. 39 indexed citations

10.

Evers, Bastiaan, Eva Schut, Eline van der Burg, et al.. (2009). A High-Throughput Pharmaceutical Screen Identifies Compounds with Specific Toxicity against BRCA2-Deficient Tumors. Clinical Cancer Research. 16(1). 99–108. 66 indexed citations

11.

Welsem, Tibor van, Floor Frederiks, Kitty F. Verzijlbergen, et al.. (2008). Synthetic Lethal Screens Identify Gene Silencing Processes in Yeast and Implicate the Acetylated Amino Terminus of Sir3 in Recognition of the Nucleosome Core. Molecular and Cellular Biology. 28(11). 3861–3872. 49 indexed citations

12.

Kuijl, Coenraad, Nigel D. L. Savage, Marije Marsman, et al.. (2007). Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. Nature. 450(7170). 725–730. 256 indexed citations

13.

Harlan, John E., David A. Egan, Uri S. Ladror, et al.. (2003). Driving Affinity Selection by Centrifugal Force. Assay and Drug Development Technologies. 1(4). 507–519. 6 indexed citations

14.

Lin, Richard J., David A. Egan, & Ronald M. Evans. (1999). Molecular genetics of acute promyelocytic leukemia. Trends in Genetics. 15(5). 179–184. 96 indexed citations

15.

Scotto, Kathleen W. & David A. Egan. (1998). Transcriptional regulation of MDR genes. Cytotechnology. 27(1-3). 257–269. 25 indexed citations

16.

Baker, William R., Anthony K. L. Fung, Hollis D. Kleinert, et al.. (1992). Nonpeptide renin inhibitors employing a novel 3-aza (or oxa)-2,4-dialkyl glutaric acid moiety as a P2/P3 amide bond replacement. Journal of Medicinal Chemistry. 35(10). 1722–1734. 12 indexed citations

17.

Edalji, Rohinton, Edward Tam, Steven Pratt, et al.. (1992). High-level expression of recombinant human FK-binding protein from a fusion precursor. Journal of Protein Chemistry. 11(3). 213–223. 19 indexed citations

18.

Fesik, Stephen W., Robert T. Gampe, H. L. Eaton, et al.. (1991). NMR studies of [U-13C] cyclosporin A bound to cyclophilin: bound conformation and portions of cyclosporin involved in binding. Biochemistry. 30(26). 6574–6583. 148 indexed citations

19.

Holzman, Thomas F., Caroline Chung, Rohinton Edalji, et al.. (1990). Recombinant human prorenin from CHO cells: Expression and purification. Journal of Protein Chemistry. 9(6). 663–672. 23 indexed citations

20.

Luly, Jay R., Nwe Y. BaMaung, Anthony K. L. Fung, et al.. (1988). Renin inhibitors. Dipeptide analogs of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency. Journal of Medicinal Chemistry. 31(12). 2264–2276. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact